Can Actinogen’s Xanamem Transform Alzheimer’s Treatment? Interim Trial Data Due Jan 2026

• FY25 net loss of $14.7 million, a 13% increase from prior year
• XanaMIA Phase 2b/3 Alzheimer’s trial over 50% enrolled, interim analysis due January 2026
• Positive Phase 2a XanaCIDD depression trial results reinforce Xanamem’s clinical activity
• Secured $11.1 million capital raise, $9 million R&D tax rebate, and $13.8 million non-dilutive funding